AI assistant
Sending…
Wave Life Sciences Ltd. — Director's Dealing 2017
Jan 28, 2017
31900_dirs_2017-01-27_74c9c57f-234f-46c1-bb9e-6cb83efb06b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2017-01-25
Reporting Person: Vargeese Chandra (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-01-25 | Ordinary Shares | A | 9800 | $0.00 | Acquired | 9800 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-01-25 | Share Option (right to buy) | $29.05 | A | 19500 | Acquired | 2027-01-25 | Ordinary Shares (19500) | Direct |
Footnotes
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021.
F2: The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021.
More from Wave Life Sciences Ltd.
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
Apr 28
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 21
Regulatory Filings
2026
Apr 15
Major Shareholding Notification
2026
Mar 31
Director's Dealing
2026
Mar 31
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Feb 28
Annual Report
2026
Feb 26